FDA Updates Kaletra Labeling

"The Kaletra (lopinavir/ritonavir) product labeling was updated to include drug-drug interaction information with etravirine, rilpivirine and simeprevir and to update the Use in Specific Populations, Pediatric Use subsection with information from a clinical trial that investigated the use of a once daily dosing regimen."   The updated labeling will be available soon at the FDA website.   More information is available: FDA: Press release AIDSinfo: Patient fact sheet on Kaletra